Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma

We thank Professors Michael Rehli, Yoshiaki Ito, and Kristian Helin for gifting plasmids, Dr. Alasdair MacKenzie (University of Aberdeen) for helpful discussion, and Mr. Takashi Mizukami, Ms. Ryoko Tokuda, and Ms. Sanae Funaoka (Kanazawa University) for technical assistance.Peer reviewedPublisher PD

膵内分泌腫瘍における分泌顆粒の電顕的及び免疫組織化学的研究

金沢大学医学部研究課題/領域番号:61770217, 研究期間(年度):1986出典：研究課題「膵内分泌腫瘍における分泌顆粒の電顕的及び免疫組織化学的研究」課題番号61770217（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） （https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-61770217/）を加工して作

FISHによる胃癌染色体17p(p53locus)の増減に関する研究

金沢大学医学部癌抑制遺伝子p53は17番染色体の短腕17p13.1に位置しており、その点突然変異とallelic lossによって機能が障害されることが知られている。本研究ではジゴキシゲニンで標識した17p13.1に特異的なコスミドプローブとビオチンで標識した17番染色体のcentomericプローブを用いてdual-color in situ hybridizationを行い、個々の胃癌細胞におけるp53遺伝子のコピー数を知るとともに、その相対的増減を観察した。またfluoresence in situ hybridizationの結果はSouthern blot法で検出した17p13.3のloss of heterozygosity(LOH)の有無、及びp53蛋白に対する抗体(RSP53)を使って免疫組織化学的に検出したp53蛋白の異常核内蓄積の有無と比較検討した。各症例で150個以上の胃癌細胞を観察し60%以上の癌細胞でp53遺伝子のシグナルがcentromereのシグナルより少ない場合を欠失(+)とし、それ以外の場合を欠失(-)とした。尚、前者のシグナルが後者のシグナルより多い症例は認められなかった。検索した42症例中、欠失を認めたものは15例であり、scirrhous carcinomaの1例を除いて全例にLOHを認めた。これらの症例では17p13.1の欠失によりallelic lossがおこっていると考えられた。欠失(-)であった27例中10例はdisomyでかつLOH(+)であり、17p13.3を含み17p13.1よりtelomere側のdeletionがおこっている可能性が示唆された。また11例はLOH、p53の核内蓄積いずれも認められず、p53遺伝子の異常は確認できなかった。残る4例ではLOH(-)にもかかわらずp53蛋白の異常核内蓄積が顕著に認められ、点突然変異による異常p53蛋白によるnegative dominantの機構が働いている可能性が強く示唆された。To understand better the role of p53 deletion in gastric adenocarcinoma, 42 cases were examined by dual-color fluorescence in situ hybridization (FISH).Probes for centromere 17 and the p53 locus (17p13.1) were hybridized simultaneously to interphase cancer cells to analyze p53 and chromosome 17 copy numbers on a cell by cell basis. The result was compared with the loss of heterozygosity (LOH) for probe YNZ22 at 17p13.3 detected by restriction fragment length polymorphism, and nuclear overexpression of p53 proteins examined immunohistochemically with anti-p53 protein antibody (RSP53). Delection was difined as when the fraction with decreased number for p53 gene signals compared with centromeric signals including monosomy fractions exceeded 60% of cell nuclei counted. Eleven of 15 cases showing deletion also showed LOH and nuclear overexpression of p53 protein. In these cases allelic loss was thought to be caused by physical deletion of 17p13.1 and point mutation of the remaining gene was highly suggestive. Five cases with neither deletion nor LOH had large population of cancer cells over-expressing p53 protein. This suggested mutant form of the p53 protein functioned in a dominant negative fashion in these cases. Other 10 cases without deletion showed LOH in spite of being disomic for both the centromeric and p53 probes. Remaining 12 cases showed neither deletion, LOH nor overexpression of p53 protein, thus it was very likely that p53 gene were not implicated in malignant progression in these cases. It was concluded that FISH is a useful tool to analyze aberrations of p53 gene in gastric adenocarcinoma.研究課題/領域番号:05670170, 研究期間(年度):1993 – 1994出典：研究課題「FISHによる胃癌染色体17p(p53locus)の増減に関する研究」課題番号05670170（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） （https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-05670170/056701701994kenkyu_seika_hokoku_gaiyo/）を加工して作

Thyroidectomy using pure natural orifice transluminal endoscopic surgery in a porcine model

Surgical procedures for thyroid disease that provide cosmetically acceptable results are in demand. Natural orifice transluminal endoscopic surgery (NOTES) is performed through natural orifices and thus avoids incision of the body wall. This study aimed to develop an incision-free surgical procedure for thyroid lobectomy using pure NOTES with an oral approach. In six pig carcasses, an incision was made between the mandible and subcutaneous tissue under direct vision. After subcutaneous dissection and identification of the hyoid bone, the operative field was developed under endoscopic view. After the thyrohyoid membrane was identified, dissection was continued along the thyroid cartilage until the cricoid cartilage was identified and the thyroid isthmus was reached. An original retractor was inserted between dissected tissues to lift and fix the carcass. The thyroid gland was successfully removed through the incision. Similar macroscopic and histological findings were observed on the normal and treated sides, with no damage to the recurrent laryngeal nerves. The times required for securing the operative field and thyroidectomy improved with each operation. This study suggests the feasibility and safety of using pure NOTES for thyroidectomy through a subcutaneous route with an original retractor

Detection of CCND1 gene copy number variations using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization methods

金沢大学医薬保健研究域医学系The CCND1 locus is located in 11q13 and encodes the G1–S regulatory protein, cyclin D1. Cyclin D1 is frequently amplified in various types of cancers, and is an attractive potential therapeutic target. Multiplex ligation-dependent probe amplification (MLPA) is a new, high-resolution method for the detection of amplification of numerous genes including CCND1 in small amounts of DNA fragments derived from formalin-fixed, paraffin-embedded material in a single reaction. This approach is, however, based on PCR and averages many different cells, so validation by morphological methods such as fluorescence in situ hybridization (FISH) is theoretically mandatory. Here we describe detection of CCND1 gene copy number variations by commercially available MLPA kits and FISH using a bacterial artificial chromosome (BAC) probe. © Springer Science+Business Media, LLC 2018.Embargo Period 12 month

Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization

New and effective treatments for advanced gastric cancer are urgently needed. Cyclins E and D1 form a complex with cyclin-dependent kinase 2, 4, or 6 to regulate G1-S transition. The G1-S regulatory genes encoding cyclin E (CCNE1), cyclin D1 (CCND1), and CDK6 (CDK6) are frequently amplified in gastric cancer and may therefore influence molecularly targeted therapies against ERBB2 or EGFR when coamplified. A total of 179 formalin-fixed and paraffin-embedded gastric cancer specimens were examined for these gene amplifications by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Amplification of at least 1 G1-S regulatory gene was found in 35 tumors (CCNE1 amplification, 15% of samples; CCND1, 6%; CDK6, 1%). In 13 of the 35 tumors, dual-color fluorescence in situ hybridization identified coamplification of the G1-S regulatory genes with ERBB2, EGFR, and/or KRAS in single cancer nuclei. The observation that cells with G1-S regulatory gene amplification contained clonal subpopulations with coamplification of ERBB2, EGFR, or KRAS in 5 early and 3 advanced cancers suggests that amplification of the G1-S regulatory genes represents an early event, which precedes ERBB2, EGFR, or KRAS amplification. Amplified CCNE1, CCND1, and CDK6 in advanced gastric cancer may be potentially useful as direct targets for molecular therapy or for combination therapy with ERBB2 or EGFR inhibitors. Multiplex ligation-dependent probe amplification could be a useful tool for identification of patients who would benefit from such therapies. © 2016 Elsevier Inc.Embargo Period 12 month

Overexpression and gene amplification of both ERBB2 and EGFR in an esophageal squamous cell carcinoma revealed by fluorescence in situ hybridization, multiplex ligation-dependent probe amplification and immunohistochemistry

EGFR and ERBB2 belong to the EGFR gene family. In esophageal squamous cell carcinomas (SCCs), amplification of EGFR or ERBB2 is usually mutually exclusive. EGFR amplification occurs in approximately 15% of SCCs, ERBB2 occurs in less than 5%. Here, we report the co-amplification of EGFR and ERBB2 in an ulcerative and infiltrating-type SCC that measured approximately 4.2 × 2.7 × 1.2cm with a superficial lesion occurring in the thoracic esophagus of a 72-year-old man. Multiplex ligation-dependent probe amplification using representative tumor sections showed gain of CCND1 and coincident amplification of ERBB2 or EGFR or neither. Immunohistochemistry and fluorescence in situ hybridization revealed that the tumor comprised three cancer-cell populations: well-differentiated SCC with high-level ERBB2 amplification and ERBB2 overexpression, more infiltrative poorly-differentiated SCC with high-level EGFR amplification and EGFR overexpression, and poorly-differentiated SCC lacking any ERBB2 or EGFR abnormality. These three populations each had low-level CCND1 amplification and nuclear cyclin D1 overexpression. This histological topology and gene amplification combinations suggested that genetic instability first produced CCND1 amplification, and then ERBB2 or EGFR gene amplification occurred. It is further speculated that during cancer progression and clonal selection indecisive predominance of either clone caused the rare co-amplification of ERBB2 and EGFR in a single chimeric tumor. © 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.発行後1年より全文公

Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas

金沢大学大学院医学系研究科がん細胞学This study was conducted to assess the frequencies of protein overexpression and gene amplification of Myc and to identify the mechanisms of Myc gene amplification, especially with regards to its possible coamplification with ERBB2 or EGFR in gastric adenocarcinomas. By immunohistochemical analysis of a total of 300 formalin-fixed and paraffin-embedded gastric adenocarcinomas, the nuclear overexpression of MYC was found in 47 tumors (16%). A fluorescence in situ hybridization (FISH) analysis revealed that nine (19%) of the 47 tumors with protein overexpression had cancer cells with high levels of Myc amplification, whereas only seven (6%) of the 122 tumors without protein overexpression showed high-level Myc gene amplification. Such Myc amplification was significantly correlated with positive nuclear protein overexpression. The coamplification of ERBB2 or EGFR with Myc that was found in six and four cases, respectively, is believed to be non-incidental because those frequencies were significantly higher than the individual frequencies observed for the total examined cases (ERBB2: 7%; EGFR: 4%). The high levels of gene amplification of these three genes, as visualized by FISH, could be broadly classified into two typical types, namely, \u27multiple scattered signals\u27 and \u27large clustered signals\u27. Using two-color FISH, the coexistence of coamplified Myc and ERBB2, or Myc and EGFR, within single nuclei in various combinations of amplification types and copy numbers, could be ascertained in all nine cases, including one in which the synchronous \u27multiple scattered type\u27 coamplification of Myc and ERBB2 was observed. In three tumors, coamplification of ERBB2 and EGFR was found; however, ERBB2- and EGFR-amplified cell populations were separate and mutually exclusive. We propose that the non-incidental coamplification of Myc and either ERBB2 or EGFR occurred through translocation and subsequent rearrangement. © 2007 USCAP, Inc All rights reserved

Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma

Neural epidermal growth factor-like like (NELL) 1 and 2 constitute a family of multimeric and multimodular extracellular glycoproteins. Although the osteogenic effects of NELL1 and functions of NELL2 in neural development have been reported, their expression and functions in cancer are largely unknown. In this study, we examined expression of NELL1 and NELL2 in renal cell carcinoma (RCC) using clinical specimens and cell lines. We show that, whereas NELL1 and NELL2 proteins are strongly expressed in renal tubules in non-cancerous areas of RCC specimens, their expression is significantly downregulated in cancerous areas. Silencing of NELL1 and NELL2 mRNA expression was also detected in RCC cell lines. Analysis of NELL1/2 promoter methylation status indicated that the CpG islands in the NELL1 and NELL2 genes are hypermethylated in RCC cell lines. NELL1 and NELL2 bind to RCC cells, suggesting that these cells express a receptor for NELL1 and NELL2 that can transduce signals. Furthermore, we found that both NELL1 and NELL2 inhibit RCC cell migration, and NELL1 further inhibits RCC cell adhesion. These results suggest that silencing of NELL gene expression by promoter hypermethylation plays roles in RCC progression by affecting cancer cell behavior. We found that the down-regulation of NELL1 and NELL2 in renal cell carcinoma (RCC) is in part due to the hypermethylation of CpG islands in their putative promoter regions. Furthermore, we found that NELL1 suppresses and NELL2 partially suppresses RCC cell migration, and NELL1 further inhibits RCC cell adhesion. © 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association